Trial Profile

Clinical trial of Vinorelbine Tartrate Liposome Injection in China

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 30 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vinorelbine (Primary)
Indications Cancer
Focus Adverse reactions
Sponsors CSPC Pharmaceutical Group

Most Recent Events

30 Apr 2022 New trial record
27 Apr 2022 According to a CSPC Pharmaceutical Group Limited media release, China Food and Drug Administration of the Peoples Republic of China has granted clinical trial approval for carrying out clinical trials in China.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com